Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
|Articles|December 19, 2005
Depakote ER OK'd for symptoms of bipolar disorder
Advertisement
The FDA has given the nod to Abbott's Depakote ER (divalproex sodium) tablets for the treatment of mania or mixed episodes with or without psychotic features associated with bipolar disorder. Depakote ER is the once-daily formulation of Depakote tablets, which has been a treatment for bipolar disorder since its approval in 1995.
Advertisement
Related to this article
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.
Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Generic Drug Costs Burdening Patients as Much as Brand Name Options
3
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
4
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
5